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CKB gene expressionThe ectopic expression in peripheral blood cells of the brain-type creatine kinase (CKB) is an autosomal domi-
nant inherited anomaly named CKBE (MIM ID123270). Here, we characterized the CK activity in serum, platelets
(PLT) and leukocytes (WBC) of 22 probands (from 8 unrelated families) and 10 controls. CK activity was mea-
sured by standard UV-photometry. Expression of the CKB genewas analyzed by real-time PCR andWestern blot-
ting. DNA sequencing including bisulfite treatment was used for molecular analysis of the CKB gene. Serum CK
levelswere comparable between probands and controls. CKBE probands revealed significantly higher CK activity
in PLT (3.7±2.7 versus 179.2±83.0 U/1012 PLT; pb0.001) and WBC (0.4±0.3 versus 2.6±2.1 U/109 WBC;
p=0.004). Inhibitory anti-CKM antibodies did not affect CK activity indicating that the CK activity is generated
exclusively by the CK-BB isoenzyme. CKB mRNA and protein levels were significantly higher in PLT and WBC
from probands compared to controls. Re-sequencing of the entire CKB gene and methylation analysis of a CpG
island revealed no alteration in CKBE probands. The genetic basis of CKBE remains unclear, however, we propose
that a de-methylated CKB gene is inherited that leads to high CKB expression levels in myeloic precursor cells in
the bone marrow.
© 2011 Elsevier Inc. All rights reserved.Introduction
Creatine kinase (CK, ATP: creatine phosphotransferase, EC 2.7.3.2)
is present in tissues with high energy turnover such as muscle and
nervous tissues. Because of the dimeric structure of human CK,
three different cytosolic isoenzymes CK-MM, CK-MB and CK-BB can
be distinguished. In skeletal muscle, nearly 100% of the activity results
from the MM isoenzyme, in heart muscle, 5–25% from the MB hybrid
form and in brain and nerve tissue nearly 100% are of the BB isoen-
zyme. For diagnostic Monitoring of CK activity in serum or plasma is
widely used in the diagnosis of myopathies and encephalopathies
[1–3].
During a newborn screening program for Duchenne muscular dys-
trophy in the late 1970s [4] using a dry spot test of whole blood [5]
some newborns with a positive test with respect to this screening
program were found. However, the serum CK was in the normalnsmedizin und Immunologie,
ax: +49 621 3706 9496.
g.de (P. Bugert).
rights reserved.range and no muscle disease present, that is, the tests were “false
positive”. To our surprise, we found in one family unusually high
levels of CK-BB within the erythrocyte fraction and this anomaly
was autosomal dominant transmitted [6]. In some families unusually
high levels of this enzyme within platelets were identified. Mean-
while, in this screening program 501,000 newborns were tested
and 132 were found “false positive” with respect to the screening
program (unpublished data). This ectopic expression of CKB (CKBE,
MIM ID 123270) in blood cells is an autosomal dominant inherited
anomaly with an estimated frequency of about 1 in 5000 persons.
The underlying CKBE mutation has been mapped to chromosome
14q32 where the CKB gene is located [7]. However, the molecular
basis of this phenomenon remains unknown.
In this study, we re-investigated CK activity in serum, platelets and
leukocytes from CKBE probands of eight unrelated families and in
normal controls. We further characterized the isoenzyme using inhib-
itory antibodies against CKM. The CKB expression in platelets and
leukocytes was determined at the mRNA and the protein level in pro-
bands and normal controls. The promoter, silencer and the coding
region of the CKB gene were analyzed by re-sequencing. In addition,
DNA methylation was determined by bisulfite sequencing.
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Subjects
Because of the need for rapid separation of the blood cells, only
families living in Southern Germany were included. Therefore,
it was achievable to start cell separation within 3 h of blood with-
drawal. From eight unrelated families 22 probands with previously
diagnosed high levels of CK activity were included. In addition, we
analyzed a control group with three normal individuals from the fam-
ilies and seven unrelated controls (healthy volunteers). For blood
collection standard systems (Sarstedt, Nümbrecht, Germany) were
used to obtain serum, EDTA blood for automated cell counting (Cell-
Dyn 3700; Abbott), and citrated whole blood for isolation of platelets
and leukocytes. The baseline characteristics of all study individuals
are summarized in Table 1.
Isolation of blood cells
Platelets were isolated and leukocyte-depleted according to a pro-
tocol published earlier [8]. Briefly, platelet-rich plasma (PRP) was
obtained from citrated blood after centrifugation for 20 min at
150 g. PRP was leukocyte-depleted with the use of Purecell PL leuko-
cyte removal filters (Pall Medical GmbH; Bad Kreuznach, Germany).
Leukocytes (WBC) were obtained from the residual citrated blood
after lysis of the red blood cells. Cell numbers of the platelet (PLT)
and the WBC fraction were determined using automated cell
counting.
Creatine kinase assays
CK activity was measured in an optical test using a standard test
system (CK; Roche Diagnostics, Mannheim, Germany). A similar test
for determination of the CK-MB isoenzyme included a mixture of
four monoclonal antibodies (mouse) against human CKM with an
inhibiting capacity of more than 99% (CK-MB; Roche). In both tests
the reduction of NADP was followed at 340 nm in a spectral pho-
tometer (Hitachi Life Science; Mannheim, Germany).
Relative CKB mRNA quantification by real-time PCR
Total platelet RNAwas extracted as described before [9]. From leu-
kocytes total RNA was extracted using a commercial kit (RNeasy Mini
Kit; Qiagen, Hilden, Germany). First strand cDNA synthesis was per-
formed using Transcriptor First Strand cDNA Synthesis Kit (Roche).
Real-time PCR for detection of the house keeping genes GAPDH and
YWHAZ as well as the CKB gene was performed on a LightCycler 480Table 1






Age, mean±SD (range) 35.8±20.3 45.7±15.5 0.183
Male, % (n) 68% (15) 30% (3) 0.062
Blood values
RBC, mean±SD [M/μl] 5.4±0.7⁎⁎ 4.7±0.2 0.005
HGB, mean±SD [g/dl] 14.7±2.0 14.2±0.6 0.468
PLT, mean±SD [K/μl] 282.5±71.3 279.4±34.9 0.896
WBC, mean±SD [K/μl] 6.9±1.3 6.1±1.1 0.117
Creatine kinase activity
Serum CK, mean±SD [U/L] 55.3±33.6 36.2±28.5 0.130
PLT CK, mean±SD [U/1012 PLT] 179.2±83.0 3.7±2.7 b0.001
WBC CK, mean±SD [U/109 WBC] 2.56±2.09 0.35±0.27 0.004
⁎ Comparison of the two groups by t-test or Fisher's exact test (for gender); signifi-
cant differences showed p-valuesb0.05.
⁎⁎ Significantly higher RBC counts in probands were due to one Turkish family (four
individuals) with thalassemia minor.system (Roche) using universal probes according to standard proto-
cols. Cp values were used for normalization and relative quantification
of mRNA levels according to geNorm algorithms [10].
Relative CKB protein quantification by Western blotting
Total protein extracts from platelets and WBCs of probands and
controls were processed for Western blotting using standard proce-
dures. The CKB protein was detected by a goat polyclonal antibody
(clone N-20; Santa Cruz Biotechnology, Inc., Heidelberg, Germany).
For relative quantification the same blots were stripped and re-
hybridized using a monoclonal anti-actin antibody (clone C-11;
Santa Cruz Biotechnology). Images from ECL detection of protein
bands were taken by a 12-bit CCD camera and further processed
using image analysis software (LabWorks 4.5; UVP Ltd., Upland CA,
USA).
DNA sequencing of the CKB gene
For promoter and exon re-sequencing genomic DNAwas prepared
from EDTA-anticoagulated blood samples using a common salting-
out method. PCR primers were developed with the help of the prim-
er3 software [11]. Due to high GC content PCR amplification of the
promoter region and exon 1 was achieved using specialized kits
(GC-rich PCR system, Roche). PCR fragments were sequenced directly
after purification in both directions by applying the same amplifying
primers or additional primers (Table 2) and the dideoxy chain termi-
nation method (DYEnamic ET Kit, GE Healthcare, Munich, Germany)
on a MegaBACE500 sequencer. For bisulfite sequencing genomic
DNA was isolated from EDTA-anticoagulated blood samples using a
commercial kit (QIAamp DNA Blood Mini Kit; Qiagen). Bisulfite con-
version was done using EpiTect Bisulfite Kit (Qiagen). The CpG island
was amplified and sequenced using primers given in Table 2.
Statistical evaluation
The statistical comparison of blood and CK activity values as well
as CKB mRNA and protein expression levels was performed using
the SPSS statistical software (SPSS v 12.0; SPSS, Munich, Germany).
P-valuesb0.05 represented significant differences.
Results
Inheritance of the CKBE phenotype in eight unrelated families
The CKBE phenotype could be confirmed by a positive test CK
activity in blood cells and normal CK activity in the serum in 22 pro-
bands from eight unrelated families. All pedigrees indicate an autoso-
mal dominant mode of inheritance (Fig. 1). Three of the probandsTable 2
Primers for re-sequencing and bisulfite sequencing of the CKB gene.
Region Forward (5′–3′) Reverse (5′–3′)
Silencer ACAGATGAGGGTCCCTGATG ACTCGAGGACGCTTGGGTTC
Promoter TGCGGGCACCTTGAGGAAG CTTTGCACGCAGCGCCCCTAGCC
Exon 1 CCAATGGAATGAATGGGCTA CAGCTTCAGTGCGTTGTG
Exon 2 CTGAGTGGTACGCGGGAG TGCAGGTTGTCGGGGTTG
Exon 3–4 CTTCACGCTGGACGACG GGGCGACGTAAACAAAAGC
Exon 5 ACTGGACGCCCGCAGAT GAGAGGGAAAGCGGAGGTAG




Exon 3 GCCACCCGTACATCATG TGCAGGTTGTCGGGGTTG
Exon 7 CCTGTAGGGGTTTCAGGCA CTGGGGAGACAGCAAGTCA
Bisulfite sequencing
CpG ATCCAAGGACCTGAGGTTTCGG GGGACGCGGCCAAGGTCAGCG
Fig. 1. Pedigrees of the eight CKBE families included in this study. Gray symbols denote
individuals with CKBE phenotype; open symbols denote unaffected individuals.
Crossed-out symbols indicate individuals that have not been re-investigated in this
study, however, diagnosis of the CKBE phenotype was obtained in former investiga-
tions. For the present study each individual was given a sample code (e.g. A-1-1 from
family A).
Fig. 2. Box plots showing total CK activity (left panel) in serum and lysates of platelets
(PLT) and leukocytes (WBC) of controls (n=10; white boxes) and CKBE probands
(n=22; gray boxes). Boxes show the 25th to 75th percentile with the median indicat-
ed by the line inside each box. Whiskers represent the 1.5 interquartile range (IQR) and
individuals with values outside the 1.5 IQR range are marked by symbols (ο or *) and
the corresponding sample number. The addition of monoclonal anti-CKM antibodies
(right panel) significantly inhibited serum CK activity but did not affect CK activity in
PLT or WBC.
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from previous screening tests. Thirty years after the initial investiga-
tion the former newborns are adults and all of them are in good
health. They did not show any signs of muscular dystrophy, platelet
dysfunction or any other diseases. All probands showed normal
blood cell values (Table 1) with one exception: in the Turkish family
(Family F, Fig. 1) all four probands exhibited red cell data indicating
thalassemia minor.
CK activity in serum and blood cells
The CK activity was measured in platelets, leukocytes and serum of
10 controls (seven unrelated controls and three normal controls from
three of the families) and 22 probands (Table 1 and Fig. 2). Serum levels
of CK activity were comparable between CKBE probands and controls
(mean±SD: 55.3±33.6 versus 36.2±28.5 U/L; p=0.130). In platelets
we found a more than 50-fold higher CK activity in the probands
compared to controls (179.2±83.0 versus 3.7±2.7 U/1012 platelets;
pb0.001). In leukocytes the difference was less prominent (approxi-
mately 7-fold higher in probands), however, still significant (2.6±2.1
versus 0.4±0.3 U/109 leukocytes; p=0.004). In order to further charac-
terize the structure of the active enzyme in the different blood fractions
we used a standard assay that included inhibitory antibodies againstCKM and compared the values with the total CK activity. As expected,
in serum samples of both probands and controls the anti-CKM anti-
bodies significantly inhibited CK activity indicating the CK-MB isoen-
zyme (Fig. 2). In platelet and leukocyte samples of probands no
significant difference of CK activity could be observed after anti-CKM in-
cubation. Thus, the CK activity in platelets and leukocytes of both CKBE
proband and controls resulted exclusively from the CK-BB isoenzyme.
CKB expression levels in platelets and leukocytes
We determined relative mRNA levels of the CKB gene compared to
mRNA levels of two reference genes (GAPDH and YWHAZ) in platelet
RNA from of 16 probands and 8 controls. Probands revealed sig-
nificantly higher mRNA levels compared to controls (p=0.005)
and the relative CKB mRNA levels strongly correlated (r=0.578;
p=0.003) with the CK activity in platelets (Fig. 3). Very similar
results could be obtained at the protein level by using Western blot-
ting. The relative CKB protein expression level was significantly
higher in platelets of probands compared to controls (p=0.001)
Fig. 3. Levels of CKBmRNA in platelets of probands (n=16) and controls (n=8) deter-
mined by real-time PCR. For relative quantification the CKB mRNA levels were com-
pared to house keeping genes (GAPDH and YWHAZ) using geNorm normalization.
(A) Probands showed significantly higher CKB mRNA levels compared to controls.
(B) The CKBmRNA levels in all tested individuals significantly correlated with CK activ-
ity in platelets.
Fig. 4. Levels of CKB protein in platelets (PLT) of probands (n=10) and controls
(n=5) determined by Western blotting (A). The polyclonal anti-CKB antibody specif-
ically detected a protein band of expected size (43 kDa). (B) For relative quantification
the intensities of the CKB and actin protein bands on the same blot were compared
using image analysis software. Probands showed significantly higher CKB protein levels
compared to controls. (C) The CKB protein levels in all tested individuals significantly
correlated with CK activity in platelets.
Fig. 5. Levels of CKB protein in leukocytes (WBC) of probands (n=8) and controls
(n=4) determined by Western blotting (A). The polyclonal anti-CKB antibody specif-
ically detected a protein band of expected size (43 kDa). (B) For relative quantification
the intensities of the CKB and actin protein bands on the same blot were compared
using image analysis software. Probands showed significantly higher CKB protein levels
compared to controls. (C) The CKB protein levels in all tested individuals tended to
correlate with CK activity in WBC without reaching statistical significance.
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(r=0.664; p=0.004) (Fig. 4). In addition, the relative protein ex-
pression significantly correlated with relative CKB mRNA levels
(r=0.751; p=0.001; data not shown). Western blotting experi-
ments were also performed on protein extracts from WBC (Fig. 5).
CKBE probands showed significantly higher CKB protein levels
(p=0.001) also in WBC. We found a moderate correlation of CKB
protein expression and CK activity in WBC that did not reach statisti-
cal significance (r=0.449; p=0.166).
Molecular analysis of the CKB gene
Direct sequencing of the promoter and the coding region of the
CKB gene was done in all probands and controls. We found no func-
tional mutation. Two synonymous SNPs in exon 4 and exon
8 (rs1136165, Arg152Arg; rs1803283, Glu364Glu) were detected,
which were in strong linkage. Genotyping for both SNPs of all
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frequencies (data not shown). In addition, we sequenced the entire
CKB silencer region described by Ritchie et al. [12] at position −390
to −1150 upstream of the transcription start site (TSS) in all CKBE
probands and controls. An INDEL (GGGGG/GGGG–) polymorphism
in a polyG stretch (G4/5-T-G4-C-G5) at position −426 was identified
in probands as well as in controls. No other DNA sequence variation
could be found.
For DNA methylation analysis we first analyzed the entire CKB se-
quence for the localization of possible CpG islands using the EMBOSS
CpGPlot tool (www.ebi.ac.uk/Tools/emboss/cpgplot/). A CpG island
was predicted with 205 bp in length including 32 CpG sites in the
promoter and exon 1 region (Fig. 6). Bisulfite sequencing of the CpG
island indicated complete methylation in leukocyte DNA samples
from probands and controls (data not shown).
Discussion
The unusually high CK activity in platelets and leukocytes of pro-
bands from eight families is genetically transmitted in an autosomal
dominant way. The activity seems exclusively generated by the CK-
BB isoenzyme because the anti-CKM antibody did not affect CK activ-
ity in platelets and leukocytes. In an earlier study from 1978 we
described the presence of CK-BB in erythrocytes of three probands
from a family of Italian origin and we could not detect any CK activity
in the platelets of normal controls using a test system based on crea-
tine and ATP as substrates [6]. In the present study with the commer-
cially available test system creatine phosphate and ADP were used as
substrates. We found low CK activity in platelets and leukocytes of
normal controls and clearly showed high CK levels in CKBE probands.
A possible interference of adenylate kinase activity in these cells is
excluded by inhibiting the activity with diadenosine pentaphosphate
and AMP. In addition, we performed pre-run measurements before
addition of the substrate creatine phosphate and could not observe
a change in absorption. Furthermore, the CK activity could not be
inhibited by anti-CKM antibodies.
In cells with high and fluctuating energy demands, such as
muscle cells, a high activity of CK is responsible for the so called phos-
phocreatine shuttle. It consists of CK in cytosol and in mitochondriaFig. 6. Result of in-silico analysis of the CKB gene sequence using the EMBOSS CpGPlot
tool to locate CpG islands. A CpG island was identified downstream of the silencer
region including the transcription start site (TSS) and the entire exon 1. The start site
of the coding region (ATG) is located in exon 2.and performs fast energy transfer between mitochondria and periph-
eral energy consumers [13]. The CK activity in normal platelets and
leukocytes as measured in the present study, even at low levels, lets
us suppose that in these blood cells the phosphocreatine shuttle is of
functional relevance. Previous reports of normal blood cells confirmed
the presence of CK activity in granulocytes, astrocytes, monocytes and
at low level in platelets, but not in erythrocytes and lymphocytes
[14,15]. The CK-BB isoenzyme was also found in serum, platelets and
erythrocytes from patients with a variety of hematologic disorders,
mostly myeloproliferative diseases [16,17]. The probands of our
study (except the Turkish family with thalassemiaminor) had no clin-
ical signs of bleeding or thrombosis or any other hematological
disfunction. Thus, the substantial increase of CK activity in platelets
and leukocytes had no negative effect on the number or function of
the blood cells. However, in vitro function tests have not been done.
It could be speculated that the markedly elevated enzyme activity,
especially in platelets, results in an acceleration of the phosphocrea-
tine shuttle followed by a more rapid regeneration of ATP. Kuiper
et al. [18] demonstrated that in macrophages – under the condition
of phagocytosis – cytosolic CKB is mobilized and co-accumulates
with F-actin in nascent phagosomes to provide access to ATP. The
occurrence of CKB in blood cells under malignant conditions of
hematopoesis may be explained as a positive reaction against the ma-
lignancy. Thus, the CKBE phenotype could possibly result in a protec-
tion against malignant transformation and other stress conditions
of the cells.
The profiling of gene transcripts in normal human platelets by
microarray hybridization analysis revealed the presence of CKB but
not CKM mRNA [9]. In the present study we could confirm CKB gene
expression in platelets and leukocytes by using real-time PCR. CKM
gene transcripts could not be detected (data not shown). The relative
CKBmRNA levels were significantly higher in CKBE probands indicat-
ing that the CKB gene is upregulated at the transcriptional level.
However, the molecular basis of the upregulation remains unknown.
Neither the coding region nor the promoter or silencer region of the
CKB gene showed DNA sequence alteration in our samples. Altered
methylation patterns of the CKB promoter were described in patients
with hematologic disorders and increased CK-BB activity [17]. Unfor-
tunately, the authors described a DNA region that we could not
localize in the human CKB gene. In our investigation using DNA
from leukocytes, methylation analysis of the CpG island did not
show differences between CKBE probands and controls. We speculate
that the CKBE phenotype is due to de-methylated CKB gene in mye-
loic precursor cells such as megakaryoblasts and myeloblasts in
the bone marrow. During cell differentiation (including megakaryo-
poiesis) the CKB gene is then silenced by methylation. The increased
levels of mRNA, protein and enzymatic activity could persist in
the cells of the blood. The hypothesis of transmission of a de-
methylated CKB gene fits with the autosomal dominant inheritance
of the CKBE phenotype.Conflict of interest
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